Clinical Pharmacology & Therapeutics: Current Understanding Of Rheumatoid Arthritis Therapy
“Progress in understanding the cellular and molecular mechanisms of rheumatoid arthritis (RA), together with the availability of new therapies, has changed the way we think about RA. The paradigm shift in RA therapy has been from controlling symptoms to controlling the disease process with the abrogation of inflammation. Challenges that are still unresolved include the issues in disease prevention, treatment specificity to restore tolerance, approaches to facilitate tissue repair, and treatment optimization to fit the individual patient’s disease phenotype and comorbidity context. This review summarizes the pathogenesis-related rationales for the current therapeutic strategies in RA and for emerging therapies and potential approaches to restoring immune tolerance in RA.”
Read More: http://www.nature.com/clpt/journal/v91/n4/full/clpt2011325a.html

A drug that “blindfolds” white blood cells could provide a new way of treating rheumatoid arthritis, new research has shown.
“This is dire,” said Valerie Jensen, associate director of the Food and Drug Administration’s drug shortages program. “Supplies are just not meeting demand.”
When Venus Williams bowed out of the U.S. Open last fall due to Sjogren’s syndrome, you may have thought, What? But her problem is more common than many think. Sjogren’s belongs to a group of some 80 autoimmune diseases in which the immune system goes haywire and attacks healthy tissue and organs.